The role of interleukin-6 signaling in nervous tissue

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 6, 2016, Pages 1218-1227

  Rothaug, Michelle ^a   Becker Pauly, Christoph ^a   Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Gp130; IL 6 signaling; Multiple sclerosis; Neurodegeneration; Sleep; Trans signaling

Indexed keywords

INTERLEUKIN 6; MONOCLONAL ANTIBODIES B E8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B E4; TOCILIZUMAB; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR; PROTEIN BINDING;

DEGENERATIVE DISEASE; DISEASE COURSE; GERIATRIC DISORDER; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NERVOUS TISSUE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SLEEP; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84962016526     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.03.018     Document Type: Review

References (167)

1. Walsh J.G., Muruve D.A., Power C. Inflammasomes in the CNS. Nat. Rev. Neurosci. 2014, 15:84-97.
2. Hofer M.J., Campbell I.L. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines. Br. J. Pharmacol. 2015.
3. Hirano T., Taga T., Nakano N., Yasukawa K., Kashiwamura S., Shimizu K., Nakajima K., Pyun K.H., Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc. Natl. Acad. Sci. U. S. A. 1985, 82:5490-5494.
4. Zilberstein A., Ruggieri R., Korn J.H., Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 1986, 5:2529-2537.
5. Fuller G.M., Otto J.M., Woloski B.M., McGary C.T., Adams M.A. The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J. Cell Biol. 1985, 101:1481-1486.
6. Content J., De Wit L., Pierard D., Derynck R., De Clercq E., Fiers W. Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:2768-2772.
7. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
8. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7251-7255.
9. Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., Fiers W. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur. J. Biochem. 1986, 159:625-632.
10. Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T., Nakai S., Kishimoto T. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 1987, 6:2939-2945.
11. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
12. Galun E., Zeira E., Pappo O., Peters M., Rose-John S. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J. 2000, 14:1979-1987.
13. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
14. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., Scheller J., Rose-John S., Kado S., Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 2010, 184:1543-1551.
15. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., Ito H., Nishimoto N., Yoshizaki K., Kishimoto T., Galle P.R., Blessing M., Rose-John S., Neurath M.F. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
16. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., Jones S.A., Rose-John S., Scheller J. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
17. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., Poli V. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 1994, 180:1243-1250.
18. Hoge J., Yan I., Janner N., Schumacher V., Chalaris A., Steinmetz O.M., Engel D.R., Scheller J., Rose-John S., Mittrucker H.W. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J. Immunol. 2013, 190:703-711.
19. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., De Benedetti F., Poli V., Ciliberto G. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 1998, 187:461-468.
20. Sasai M., Saeki Y., Ohshima S., Nishioka K., Mima T., Tanaka T., Katada Y., Yoshizaki K., Suemura M., Kishimoto T. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999, 42:1635-1643.
21. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., Schutz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J.F., Lehr H.A., Autschbach F., Schurmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P.R., Rose-John S., Neurath M.F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 2000, 6:583-588.
22. Andrejko K.M., Raj N.R., Kim P.K., Cereda M., Deutschman C.S. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 2008, 29:490-496.
23. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 2011, 121:3375-3383.
24. Wang X., Lupardus P., Laporte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 2009, 27:29-60.
25. Bazan J.F. Haemopoietic receptors and helical cytokines. Immunol. Today 1990, 11:350-354.
26. Taga T., Kishimoto T. Cytokine receptors and signal transduction. FASEB J. 1992, 6:3387-3396.
27. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
28. Bauer S., Kerr B.J., Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev. Neurosci. 2007, 8:221-232.
29. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
30. Garbers C., Hermanns H.M., Schaper F., Muller-Newen G., Grotzinger J., Rose-John S., Scheller J. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012, 23:85-97.
31. Gomez C.R., Goral J., Ramirez L., Kopf M., Kovacs E.J. Aberrant acute-phase response in aged interleukin-6 knockout mice. Shock 2006, 25:581-585.
32. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995, 86:1243-1254.
33. Klein M.A., Moller J.C., Jones L.L., Bluethmann H., Kreutzberg G.W., Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia 1997, 19:227-233.
34. Morrow J.D., Opp M.R. Sleep-wake behavior and responses of interleukin-6-deficient mice to sleep deprivation. Brain Behav. Immun. 2005, 19:28-39.
35. Penkowa M., Moos T., Carrasco J., Hadberg H., Molinero A., Bluethmann H., Hidalgo J. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia 1999, 25:343-357.
36. Fattori E., Lazzaro D., Musiani P., Modesti A., Alonzi T., Ciliberto G. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur. J. Neurosci. 1995, 7:2441-2449.
37. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10061-10065.
38. Li T., He S. Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. Immunol. Cell Biol. 2006, 84:461-466.
39. Lee Y.B., Nagai A., Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 2002, 69:94-103.
40. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990, 4:2860-2867.
41. Hobbs M.V., McEvilly R.J., Koch R.J., Cardenas G.J., Noonan D.J. Interleukin-6 production by murine B cells and B cell lines. Cell. Immunol. 1991, 132:442-450.
42. März P., Cheng J.G., Gadient R.A., Patterson P.H., Stoyan T., Otten U., Rose-John S. Sympathetic neurons can produce and respond to interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3251-3256.
43. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88:1379-1406.
44. Skurk T., Alberti-Huber C., Herder C., Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 2007, 92:1023-1033.
45. May L.T., Torcia G., Cozzolino F., Ray A., Tatter S.B., Santhanam U., Sehgal P.B., Stern D. Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem. Biophys. Res. Commun. 1989, 159:991-998.
46. Castell J.V., Geiger T., Gross V., Andus T., Walter E., Hirano T., Kishimoto T., Heinrich P.C. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 1988, 177:357-361.
47. Oberg H.H., Wesch D., Grussel S., Rose-John S., Kabelitz D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. Int. Immunol. 2006, 18:555-563.
48. Hsu M.P., Frausto R., Rose-John S., Campbell I.L. Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M. Glia 2015, 63:132-141.
49. Lin H.W., Levison S.W. Context-dependent IL-6 potentiation of interferon- gamma-induced IL-12 secretion and CD40 expression in murine microglia. J. Neurochem. 2009, 111:808-818.
50. Sawada M., Itoh Y., Suzumura A., Marunouchi T. Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci. Lett. 1993, 160:131-134.
51. Lust J.A., Donovan K.A., Kline M.P., Greipp P.R., Kyle R.A., Maihle N.J. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992, 4:96-100.
52. Horiuchi S., Koyanagi Y., Zhou Y., Miyamoto H., Tanaka Y., Waki M., Matsumoto A., Yamamoto M., Yamamoto N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. 1994, 24:1945-1948.
53. Müllberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., Mackiewicz A., Heinrich P.C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 1993, 23:473-480.
54. Müllberg J., Durie F.H., Otten-Evans C., Alderson M.R., Rose-John S., Cosman D., Black R.A., Mohler K.M. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 1995, 155:5198-5205.
55. Matthews V., Schuster B., Schutze S., Bussmeyer I., Ludwig A., Hundhausen C., Sadowski T., Saftig P., Hartmann D., Kallen K.J., Rose-John S. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 2003, 278:38829-38839.
56. Althoff K., Reddy P., Voltz N., Rose-John S., Mullberg J. Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur. J. Biochem. 2000, 267:2624-2631.
57. Taga T., Kishimoto T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr. Opin. Immunol. 1995, 7:17-23.
58. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
59. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
60. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994, 300(Pt 2):281-290.
61. Saito M., Yoshida K., Hibi M., Taga T., Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol. 1992, 148:4066-4071.
62. März P., Heese K., Dimitriades-Schmutz B., Rose-John S., Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999, 26:191-200.
63. Peters M., Schirmacher P., Goldschmitt J., Odenthal M., Peschel C., Fattori E., Ciliberto G., Dienes H.P., Buschenfelde K.H.Meyer zum, Rose-John S. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 1997, 185:755-766.
64. Drucker C., Rabe B., Chalaris A., Schulz E., Scheller J., Rose-John S. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage. J. Interf. Cytokine Res. 2009, 29:711-718.
65. Campbell I.L., Erta M., Lim S.L., Frausto R., May U., Rose-John S., Scheller J., Hidalgo J. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J. Neurosci. 2014, 34:2503-2513.
66. Nowell M.A., Richards P.J., Horiuchi S., Yamamoto N., Rose-John S., Topley N., Williams A.S., Jones S.A. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 2003, 171:3202-3209.
67. Richards P.J., Nowell M.A., Horiuchi S., McLoughlin R.M., Fielding C.A., Grau S., Yamamoto N., Ehrmann M., Rose-John S., Williams A.S., Topley N., Jones S.A. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 2006, 54:1662-1672.
68. Mitsuyama K., Matsumoto S., Rose-John S., Suzuki A., Hara T., Tomiyasu N., Handa K., Tsuruta O., Funabashi H., Scheller J., Toyonaga A., Sata M. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006, 55:1263-1269.
69. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., Yancopoulos G.D., Taga T., Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82:1120-1126.
70. Jostock T., Müllberg J., Ozbek S., Atreya R., Blinn G., Voltz N., Fischer M., Neurath M.F., Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 2001, 268:160-167.
71. Benveniste E.N. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev. 1998, 9:259-275.
72. Lilja A., Nordborg C., Brun A., Salford L.G., Aman P. Expression of the IL-6 family cytokines in human brain tumors. Int. J. Oncol. 2001, 19:495-499.
73. Frei K., Fredrikson S., Fontana A., Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol. 1991, 31:147-153.
74. Maimone D., Guazzi G.C., Annunziata P. IL-6 detection in multiple sclerosis brain. J. Neurol. Sci. 1997, 146:59-65.
75. Ali C., Nicole O., Docagne F., Lesne S., MacKenzie E.T., Nouvelot A., Buisson A., Vivien D. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J. Cereb. Blood Flow Metab. 2000, 20:956-966.
76. Wagner J.A. Is IL-6 both a cytokine and a neurotrophic factor?. J. Exp. Med. 1996, 183:2417-2419.
77. Bonni A., Sun Y., Nadal-Vicens M., Bhatt A., Frank D.A., Rozovsky I., Stahl N., Yancopoulos G.D., Greenberg M.E. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 1997, 278:477-483.
78. Gruol D.L., Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 1997, 15:307-339.
79. Akaneya Y., Takahashi M., Hatanaka H. Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp. Neurol. 1995, 136:44-52.
80. Toulmond S., Vige X., Fage D., Benavides J. Local infusion of interleukin-6 attenuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci. Lett. 1992, 144:49-52.
81. Kushima Y., Hatanaka H. Interleukin-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci. Lett. 1992, 143:110-114.
82. Kushima Y., Hama T., Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci. Res. 1992, 13:267-280.
83. Hirota H., Kiyama H., Kishimoto T., Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 1996, 183:2627-2634.
84. Marz P., Heese K., Hock C., Golombowski S., Muller-Spahn F., Rose-John S., Otten U. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 1997, 239:29-32.
85. Fischer M., Goldschmitt J., Peschel C., Brakenhoff J.P., Kallen K.J., Wollmer A., Grotzinger J., Rose-John S. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 1997, 15:142-145.
86. Chucair-Elliott A.J., Conrady C., Zheng M., Kroll C.M., Lane T.E., Carr D.J. Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells. Glia 2014, 62:1418-1434.
87. Yang P., Wen H., Ou S., Cui J., Fan D. IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. Exp. Neurol. 2012, 236:19-27.
88. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
89. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J. Neural Transm. Suppl. 2006, 373-381.
90. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991, 285:111-114.
91. Wood J.A., Wood P.L., Ryan R., Graff-Radford N.R., Pilapil C., Robitaille Y., Quirion R. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993, 629:245-252.
92. Hull M., Berger M., Volk B., Bauer J. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann. N. Y. Acad. Sci. 1996, 777:205-212.
93. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 2007, 27:3338-3346.
94. Ahmed M., Davis J., Aucoin D., Sato T., Ahuja S., Aimoto S., Elliott J.I., Van Nostrand W.E., Smith S.O. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol. 2010, 17:561-567.
95. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
96. Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 2015.
97. Chin-Chan M., Navarro-Yepes J., Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front. Cell. Neurosci. 2015, 9:124.
98. Forloni G., Mangiarotti F., Angeretti N., Lucca E., De Simoni M.G. Beta-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia. Cytokine 1997, 9:759-762.
99. Sondag C.M., Dhawan G., Combs C.K. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J. Neuroinflammation 2009, 6:1.
100. Song D.K., Im Y.B., Jung J.S., Cho J., Suh H.W., Kim Y.H. Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J. Neurochem. 2001, 76:1326-1335.
101. Ringheim G.E., Szczepanik A.M., Petko W., Burgher K.L., Zhu S.Z., Chao C.C. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res. Mol. Brain Res. 1998, 55:35-44.
102. Qiu Z., Gruol D.L. Interleukin-6, beta-amyloid peptide and NMDA interactions in rat cortical neurons. J. Neuroimmunol. 2003, 139:51-57.
103. Chakrabarty P., Jansen-West K., Beccard A., Ceballos-Diaz C., Levites Y., Verbeeck C., Zubair A.C., Dickson D., Golde T.E., Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010, 24:548-559.
104. Hama T., Kushima Y., Miyamoto M., Kubota M., Takei N., Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 1991, 40:445-452.
105. Davie C.A. A review of Parkinson's disease. Br. Med. Bull. 2008, 86:109-127.
106. Bolin L.M., Strycharska-Orczyk I., Murray R., Langston J.W., Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J. Neurochem. 2002, 83:167-175.
107. McKay K.A., Tremlett H. The systematic search for risk factors in multiple sclerosis. Lancet Neurol. 2015, 14:237-238.
108. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
109. Samoilova E.B., Horton J.L., Hilliard B., Liu T.S., Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 1998, 161:6480-6486.
110. Okuda Y., Sakoda S., Bernard C.C., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 1998, 10:703-708.
111. Eugster H.P., Frei K., Kopf M., Lassmann H., Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 1998, 28:2178-2187.
112. Kruglov A.A., Lampropoulou V., Fillatreau S., Nedospasov S.A. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J. Immunol. 2011, 187:5660-5670.
113. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., Regev A., Kuchroo V.K. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496:513-517.
114. Hernandez J.B., Chang C., LeBlanc M., Grimm D., Le Lay J., Kaestner K.H., Zheng Y., Montminy M. The CREB/CRTC2 pathway modulates autoimmune disease by promoting Th17 differentiation. Nat. Commun. 2015, 6:7216.
115. Murugaiyan G., da Cunha A.P., Ajay A.K., Joller N., Garo L.P., Kumaradevan S., Yosef N., Vaidya V.S., Weiner H.L. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J. Clin. Invest. 2015, 125:1069-1080.
116. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
117. Naito Y., Takagi T., Uchiyama K., Kuroda M., Kokura S., Ichikawa H., Yanagisawa R., Inoue K., Takano H., Satoh M., Yoshida N., Okanoue T., Yoshikawa T. Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int. J. Mol. Med. 2004, 14:191-196.
118. Quintana A., Müller M., Frausto R.F., Ramos R., Getts D.R., Sanz E., Hofer M.J., Krauthausen M., King N.J., Hidalgo J., Campbell I.L. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J. Immunol. 2009, 183:2079-2088.
119. Giralt M., Ramos R., Quintana A., Ferrer B., Erta M., Castro-Freire M., Comes G., Sanz E., Unzeta M., Pifarre P., Garcia A., Campbell I.L., Hidalgo J. Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6. Glia 2013, 61:587-600.
120. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
121. Dominitzki S., Fantini M.C., Neufert C., Nikolaev A., Galle P.R., Scheller J., Monteleone G., Rose-John S., Neurath M.F., Becker C. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J. Immunol. 2007, 179:2041-2045.
122. Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi Y., Nomura S., Yoshida H., Nishikawa T., Terabe F., Ohkawara T., Takahashi T., Ripley B., Kimura A., Kishimoto T., Naka T. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9041-9046.
123. Linker R.A., Luhder F., Kallen K.J., Lee D.H., Engelhardt B., Rose-John S., Gold R. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J. Neuroimmunol. 2008, 205:64-72.
124. Briso E.M., Dienz O., Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J. Immunol. 2008, 180:7102-7106.
125. Burton M.D., Rytych J.L., Freund G.G., Johnson R.W. Central inhibition of interleukin-6 trans-signaling during peripheral infection reduced neuroinflammation and sickness in aged mice. Brain Behav. Immun. 2013, 30:66-72.
126. Ma X., Reynolds S.L., Baker B.J., Li X., Benveniste E.N., Qin H. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J. Immunol. 2010, 184:4898-4906.
127. Ogura H., Murakami M., Okuyama Y., Tsuruoka M., Kitabayashi C., Kanamoto M., Nishihara M., Iwakura Y., Hirano T. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636.
128. Marz P., Heese K., Dimitriades-Schmutz B., Rose-John S., Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999, 26:191-200.
129. Van Wagoner N.J., Oh J.W., Repovic P., Benveniste E.N. Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J. Neurosci. 1999, 19:5236-5244.
130. Pawate S., Shen Q., Fan F., Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J. Neurosci. Res. 2004, 77:540-551.
131. Lavigne M.C., Malech H.L., Holland S.M., Leto T.L. Genetic requirement of p47phox for superoxide production by murine microglia. FASEB J. 2001, 15:285-287.
132. Haider L., Fischer M.T., Frischer J.M., Bauer J., Hoftberger R., Botond G., Esterbauer H., Binder C.J., Witztum J.L., Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
133. Haines J.D., Inglese M., Casaccia P. Axonal damage in multiple sclerosis. Mt Sinai J. Med. 2011, 78:231-243.
134. Love S. Demyelinating diseases. J. Clin. Pathol. 2006, 59:1151-1159.
135. Imeri L., Opp M.R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 2009, 10:199-210.
136. Besedovsky L., Lange T., Born J. Sleep and immune function. Pflugers Arch. 2012, 463:121-137.
137. Lange T., Dimitrov S., Bollinger T., Diekelmann S., Born J. Sleep after vaccination boosts immunological memory. J. Immunol. 2011, 187:283-290.
138. Dimitrov S., Lange T., Benedict C., Nowell M.A., Jones S.A., Scheller J., Rose-John S., Born J. Sleep enhances IL-6 trans-signaling in humans. FASEB J. 2006, 20:2174-2176.
139. Keller M., Mazuch J., Abraham U., Eom G.D., Herzog E.D., Volk H.D., Kramer A., Maier B. A circadian clock in macrophages controls inflammatory immune responses. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21407-21412.
140. Hogan D., Morrow J.D., Smith E.M., Opp M.R. Interleukin-6 alters sleep of rats. J. Neuroimmunol. 2003, 137:59-66.
141. Benington J.H., Heller H.C. Restoration of brain energy metabolism as the function of sleep. Prog. Neurobiol. 1995, 45:347-360.
142. Horne J. Human slow wave sleep: a review and appraisal of recent findings, with implications for sleep functions, and psychiatric illness. Experientia 1992, 48:941-954.
143. Benedict C., Scheller J., Rose-John S., Born J., Marshall L. Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep. FASEB J. 2009, 23:3629-3636.
144. Vgontzas A.N., Zoumakis M., Bixler E.O., Lin H.M., Prolo P., Vela-Bueno A., Kales A., Chrousos G.P. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J. Clin. Endocrinol. Metab. 2003, 88:2087-2095.
145. Burgos I., Richter L., Klein T., Fiebich B., Feige B., Lieb K., Voderholzer U., Riemann D. Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav. Immun. 2006, 20:246-253.
146. Vgontzas A.N., Zoumakis M., Papanicolaou D.A., Bixler E.O., Prolo P., Lin H.M., Vela-Bueno A., Kales A., Chrousos G.P. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002, 51:887-892.
147. Brown R.E., Basheer R., McKenna J.T., Strecker R.E., McCarley R.W. Control of sleep and wakefulness. Physiol. Rev. 2012, 92:1087-1187.
148. May U., Schiffelholz T., Baier P.C., Krueger J.M., Rose-John S., Scheller J. IL-6-trans-signalling increases rapid-eye-movement sleep in rats. Eur. J. Pharmacol. 2009, 613:141-145.
149. Oyanedel C.N., Kelemen E., Scheller J., Born J., Rose-John S. Peripheral and central blockade of interleukin-6 trans-signaling differentially affects sleep architecture. Brain Behav. Immun. 2015.
150. Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78:1198-1204.
151. Lu Z.Y., Brochier J., Wijdenes J., Brailly H., Bataille R., Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 1992, 22:2819-2824.
152. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008, 151-160.
153. Brunner H.I., Ruperto N., Zuber Z., Keane C., Harari O., Kenwright A., Lu P., Cuttica R., Keltsev V., Xavier R.M., Calvo I., Nikishina I., Rubio-Perez N., Alexeeva E., Chasnyk V., Horneff G., Opoka-Winiarska V., Quartier P., Silva C.A., Silverman E., Spindler A., Baildam E., Gamir M.L., Martin A., Rietschel C., Siri D., Smolewska E., Lovell D., Martini A., De Benedetti F. P. Paediatric rheumatology international trials organisation, G. Pediatric rheumatology collaborative study, efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann. Rheum. Dis. 2015, 74:1110-1117.
154. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., Xavier R., Zemel L., Baildam E., Burgos-Vargas R., Dolezalova P., Garay S.M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A., Printo, Prcsg Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012, 367:2385-2395.
155. Garcia-Oscos F., Salgado H., Hall S., Thomas F., Farmer G.E., Bermeo J., Galindo L.C., Ramirez R.D., D'Mello S., Rose-John S., Atzori M. The stress-induced cytokine interleukin-6 decreases the inhibition/excitation ratio in the rat temporal cortex via trans-signaling. Biol. Psychiatry 2012, 71:574-582.
156. Garcia-Oscos F., Pena D., Housini M., Cheng D., Lopez D., Borland M.S., Salgado-Delgado R., Salgado H., D'Mello S., Kilgard M.P., Rose-John S., Atzori M. Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain Behav. Immun. 2015, 43:149-158.
157. Calabrese L.H., Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 2014, 10:720-727.
158. Schaper F., Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015, 26:475-487.
159. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 1999, 22:11-28.
160. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012, 503:269-292.
161. Bien-Ly N., Yu Y.J., Bumbaca D., Elstrott J., Boswell C.A., Zhang Y., Luk W., Lu Y., Dennis M.S., Weimer R.M., Chung I., Watts R.J. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 2014, 211:233-244.
162. Boado R.J., Zhang Y., Wang Y., Pardridge W.M. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 2009, 102:1251-1258.
163. Boado R.J., Zhang Y., Zhang Y., Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 96:381-391.
164. Boado R.J., Lu J.Z., Hui E.K., Pardridge W.M. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol. Pharm. 2014, 11:2928-2934.
165. Boado R.J., Zhang Y., Zhang Y., Xia C.F., Wang Y., Pardridge W.M. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug. Chem. 2008, 19:731-739.
166. Zhou Q.H., Lu J.Z., Hui E.K., Boado R.J., Pardridge W.M. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug. Chem. 2011, 22:1611-1618.
167. Müller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 1998, 98:142-144.